Shots:

• The company reported the results from the (MOMENTUM 3) trial evaluating the long-term outcomes of the HeartMate 3 left ventricular assist device in patients with advanced heart failure
• The results showed that the heart pump helps to extend the survival to 5yrs. and beyond for HF patients, improvement in a survival rate of 58% with HeartMate 3 Heart Pump over 44% with HeartMate II, reduction in deaths due to stroke, clotting, and bleeding over HeartMate II
• The device also provides clear lifesaving options along with a significant survival benefit of Abbott's heart pump technology without a heart pump or transplant who have limited therapeutic options with a median survival to ≤1yr.

Ref: Abbott | Image: Abbott